No trading action warranted. The CFO departure was pre-announced and the separation terms are standard. Monitor for appointment of a permanent CFO and next quarterly earnings for any strategic updates.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $23.02entry
- T+1 · 6mo ago +2.00%α +1.77% · $23.48
- T+5 · 6mo ago +8.04%α +6.57% · $24.87
- T+20 · 5mo ago −12.16%α −12.19% · $20.22
- T+60 · 3mo ago +27.54%α +22.70% · $29.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics formalized the separation of former CFO Daniella Beckman, who was terminated without cause effective May 1, 2026. The separation agreement provides 12 months of base salary severance, COBRA premium reimbursement for up to 12 months, accelerated vesting of equity that would have vested over the next 24 months, and an extended stock option exercise period through August 31, 2026. This is a routine administrative filing formalizing a previously announced CFO departure with standard severance terms, no new material financial information or strategic implications.
Key Facts
- CFO Daniella Beckman's employment terminated without cause effective May 1, 2026; separation agreement signed May 7, 2026
- Severance includes 12 months of base salary paid in installments and COBRA premium reimbursement for up to 12 months
- Equity acceleration: unvested time-based options and RSUs that would have vested over 24 months post-termination will accelerate and vest as of termination date
- Stock option exercise period extended through August 31, 2026 for vested options
- CFO departure was previously announced on April 10, 2026, effective April 15, 2026
Financial Impact
Severance of 12 months base salary (amount not disclosed) plus COBRA premiums for up to 12 months and accelerated equity vesting, immaterial relative to $3.4B market cap
Risk Factors
- Prolonged CFO vacancy could create operational distraction
- No permanent CFO replacement named, succession timeline unclear
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213491 |
| Document: d102174d8k.htm | 0001193125-26-213491 |
| Document: 0001193125-26-213491-index-headers.html | 0001193125-26-213491 |
| Document: 0001193125-26-213491-index.html | 0001193125-26-213491 |
| Document: 0001193125-26-213491.txt | 0001193125-26-213491 |
Track record
27 reports on TNGX
3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers